Pure Global
NCT06414915

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

A Single-arm, Open, Single-center, Prospective and Exploratory Clinical Study of Surufatinib Combined With Tislelizumab in the Treatment of Advanced Lung Cancer With Neuroendocrine Differentiation
National Cancer Center, China·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
Surufatinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
National Cancer Center, China
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Jun 01, 2027
Enrollment
29 participants
Primary outcome

Progression-Free Survival (PFS)

Summary

Currently, there are no standard treatment and relevant exploration for NSCLC patients with
 NED. The study aims to explore the efficacy and safety of surufatinib combined with
 tislelizumab in the treatment of NSCLC with NED, in order to provide a new treatment option
 for NSCLC patients with NED.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06414915
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06414915 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Center, China and is currently Not yet recruiting. The study focuses on NSCLC. Target enrollment is 29 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.